![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AMORFIX LIFE SCIENCES AND BIOGEN IDEC TO COLLABORATE ON RESEARCH FOR ALS DISEASE
AMORFIX LIFE SCIENCES AND BIOGEN IDEC TO COLLABORATE ON RESEARCH FOR ALS DISEASE
August 4, 2006
Amorfix Life Sciences Ltd., an emerging Canadian theranostics company, announced today that it has entered into a research and investment agreement with Biogen Idec of Cambridge, Massachusetts, which includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). Amorfix will conduct a planned research program with operational support and investment from Biogen Idec.
CNW Group (http://www.newswire.ca/en/releases/archive/August2006/03/c3378.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct